<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/256775-human-monoclonal-antibodies-against-human-il-4 by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:10:58 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 256775:&quot;HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN IL-4&quot;</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">&quot;HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN IL-4&quot;</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Antibodies which are specific for human interleukin-4 and their use in the treatment of IL-4 and/or IgE mediated diseases.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN IL-4<br>
The present invention relates to antibodies which are specific for human interleukin-4 (hlL-4).<br>
Allergic diseases such as atopic dermatitis, allergic rhinitis, asthma and food allergies are<br>
characteristically associated with exacerbated Th2 cell responses to innocuous environmental<br>
antigens (allergens). Allergens are captured by antigen presenting cells, processed and presented<br>
in the context of MHC Class II molecules to allergen-specific T helper (Th) cells. Allergen specific<br>
Th cells belong to the Th2 phenotype and develop from precursor T cells under the influence of<br>
interleukin-4 (IL-4). Once Th2 cells are activated, they secrete IL-4 and interleukin-13 (IL-13),<br>
which together with surface bound signals induce B cells to switch to IgE producing plasma cells.<br>
IgE molecules bind to high affinity FceR on mast cells and, after subsequent encounter with<br>
allergen, induce mast cell activation and the release of mediators of allergic reactions. Th2<br>
cytokines also promote the survival of eosinophils and the growth of mast cells which, after<br>
degranulation, also release additional Th2 cytokines capable of augmenting IgE production, Th2<br>
cell differentiation and eosinophil survival. Thus, Th2 cells play a pivotal role in the induction and<br>
development of allergic responses and therefore, antagonizing their development and/or their<br>
effector functions would be an efficient way to intervene in allergic responses.<br>
IL-4 and IL-13 share many biological activities due to the fact that both cytokines use the IL-4<br>
receptor (IL-4R)-alpha chain as a component of their respective receptor complexes. IL-13 signals<br>
through an heterodimeric complex consisting of an IL-13 binding chain (IL-13Ra1) and the IL-4Ra<br>
chain. IL-4 utilizes this IL-4Ra/IL-13Ra1 complex, called type IIIL-4R, as an alternative to the type<br>
IIL-4R, consisting of IL-4Ra chain and the common y chain (cy) shared by receptors for IL-2, IL-4,<br>
IL-7, IL-9, IL-15 and thymic stromal lymphopoietin (TSLP). Because T cells do not express<br>
IL-13Ra1, IL-13 in contrast to IL-4 does not support T cell proliferation and cannot induce the<br>
differentiation of naive human Th cells towards the Th2 phenotype (see e.g. J. E. de Vries et al.,<br>
Encyclopedia of Hormones and related cell regulators, Academic Press, 2002). IL-4 plays a pivotal<br>
role in T cell proliferation and thus in the development and maintenance of allergic diseases.<br>
IL-4 gene deficient mice or mice lacking IL-4 (see e.g. Kuhn R. et al., Science, 1991 (5032) 707:10)<br>
or the downstream signaling factor STAT6 (see e.g. Kaplan M.H. et al., Immunity, 1996 (3) 313-9)<br>
do not develop significant numbers of Th2 cells and have reduced IgE responses.<br>
We have now found antibodies with a high affinity for human IL-4 and a strong inhibitory potential<br>
of IL-4 mediated IgE synthesis by naive human B cells.<br>
In one aspect the present invention provides an human IL-4 specific antibody which binds to<br>
human IL-4 with a dissociation constant Kd of equal or less than 800 pM, such as e.g. equal or less<br>
than 200 pM.<br>
In another aspect the present invention provides an antibody having a first domain comprising in<br>
sequence the hypervariable regions CDR1, CDR2 and CDR3 and a second domain comprising in<br>
sequence the hypervariable regions CDR1', CDR2' and CDR3' selected from the group consisting<br>
of an antibody wherein<br>
a) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Ala-Met-His<br>
(GFTFSSYAMH),<br>
said CDR2 has the amino acid sequence Phe-lle-Trp-Asp-Asp-Gly-Ser-Phe-Lys-Tyr-Tyr-Ala-<br>
Glu-Ser-Val-Lys-Gly(FIWDDGSFKYYAESVKG),<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe<br>
(EGSWSPDIF),<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Ser-Arg-Ala (SQGISRA),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-lle (FNSYPI),<br>
b) said CDR1 has the amino acid sequence Gly-Phe-Thr-Leu-Ser-Ser-Phe-Gly-Met-His<br>
(GFTLSSFGMH),<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Glu-Tyr-Tyr-Ala-Asp-<br>
Ser-Val-Lys-Gly(VIWYDGSNEYYADSVKG),<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe<br>
(EGSWSPDIF),<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Arg-Ser-Ala (SQGIRSA),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Val (FNSYPV),<br>
c) said CDR1 has the amino acid sequence Gly-Phe-Thr-Leu-Ser-Ser-Tyr-GIy-Met-His<br>
(GFTLSSYGMH),<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Asn-Asn-Gln-Tyr-Tyr-Ala-Asp-<br>
Ser-Val-Lys-Gly(VIWYDGNNQYYADSCKG),<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe<br>
(EGSWSPDIF),<br>
said CDR11 has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Tyr (SQGISSY),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR31 has the amino acid sequence Phe-Asn-Ser-Tyr-Pro (FNSYP),<br>
d) said CDR1 has the amino acid sequence Gly-Asp-Thr-Phe-Ser-Ser-Tyr-Ala-lle-Ser<br>
(GDTFSSYAIS),<br>
said CDR2 has the amino acid sequence Gly-lle-lle-lle-Pro-Val-lle-Gly-Thr-Val-Asn-Tyr-Glu-Glu-<br>
Arg-Phe-Gln-Asp-Arg(GIIIPVIGTVNYEERFQD).<br>
said CDR3 has the amino acid sequence Glu-Glu-Gly-Phe-Leu (EEGFL),<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Ala (SQGISSA),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR31 has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Leu (FNSYPL),<br>
e) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Cys-Cys-Gly-Met-His<br>
(GFTFSCCGMH),<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-Asp-<br>
Ser-Val-Lys-Gly(VIWYDGSNKYYADSVKG),<br>
said CDR3 has the amino acid sequence Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Phe<br>
(DSSGSFYEYF),<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Asn-Ser-Ala (SQGINSA),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR31 has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Tyr (FNSYPY), and<br>
f) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Gly-Tyr-Gly-Met-His<br>
(GFTFSGYGMH),<br>
said CDR2 has the amino acid sequence Val-Val-Trp-Tyr-Asp-Gly-Gly-Tyr- Lys- Phe-Tyr-Ala-<br>
Asp-Ser-Val-Lys-Gly(WWYDGGYKFYADSVKG),<br>
said CDR3 has the amino acid sequence Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Leu<br>
(DSSGSFYEYL),<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Ala (SQGISSA),<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser (DAS),<br>
said CDR31 has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-His (FNSYPH).<br>
CDR1, CDR2 and CDR3 are part of the amino acid sequence of the heavy chain of such antibody<br>
and CDRT, CDR2' and CDR3' are part of the amino acid sequence of the light chain of such<br>
antibody.<br>
We also have found an antibody comprising:<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO:1 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:2, or<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO:9 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:10, or<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO: 17 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:18, or<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO:25 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:26, or<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO:33 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:34, or<br>
- the amino acid sequence of the heavy chain of a mature polypeptide of SEQ ID NO:41 and the<br>
amino acid sequence of the light chain of a mature polypeptide of SEQ ID NO:42.<br>
In a further aspect the present invention provides an antibody comprising<br>
a) a polypeptide of SEQ ID NO:1 and a polypeptide of SEQ ID NO:2, or<br>
b) a polypeptide of SEQ ID NO:9 and a polypeptide of SEQ ID NO:10, or<br>
c) a polypeptide of SEQ ID NO: 17 and a polypeptide of SEQ ID NO: 18, or<br>
d) a polypeptide of SEQ ID NO:25 and a polypeptide of SEQ ID NO:26, or<br>
e) a polypeptide of SEQ ID NO:33 and a polypeptide of SEQ ID NO:34, or<br>
f) a polypeptide of SEQ ID NO:41 and a polypeptide of SEQ ID NO:42.<br>
We further have found an antibody comprising:<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:1 further containing a<br>
leader sequence (= SEQ ID NO:3) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO:2 further containing a leader sequence (= SEQ ID NO:4), or<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:9 further containing a<br>
leader sequence (= SEQ ID NO: 11) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO:10 further containing a leader sequence (= SEQ ID NO:12), or<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:17 further containing<br>
a leader sequence (= SEQ ID NO: 19) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO: 18 further containing a leader sequence (= SEQ ID NO:20), or<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:25 further containing<br>
a leader sequence (= SEQ ID NO:27) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO:26 further containing a leader sequence (= SEQ ID NO:28), or<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:33 further containing<br>
a leader sequence (= SEQ ID NO:35) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO:34 further containing a leader sequence (= SEQ ID NO:36), or<br>
- the amino acid sequence of the heavy chain of a polypeptide of SEQ ID NO:41 further containing<br>
a leader sequence (= SEQ ID NO:43) and the amino acid sequence of the light chain of a<br>
polypeptide of SEQ ID NO:42 further containing a leader sequence (= SEQ ID NO:44).<br>
In a further aspect the present invention provides an antibody comprising<br>
a) a polypeptide of SEQ ID NO:3 and a polypeptide of SEQ ID NO:4, or<br>
b) a polypeptide of SEQ ID NO:11 and a polypeptide of SEQ ID NO:12. or<br>
5<br>
c) a polypeptide of SEQ ID NO:19 and a polypeptide of SEQ ID NO:20, or<br>
d) a polypeptide of SEQ ID NO:27 and a polypeptide of SEQ ID NO:28, or<br>
e) a polypeptide of SEQ ID NO:35 and a polypeptide of SEQ ID NO:36, or<br>
f) a polypeptide of SEQ ID NO:43 and a polypeptide of SEQ ID NO:44.<br>
Antibodies provided by the present invention are hereinafter also designated as "compound(s) of<br>
(according to) the present invention".<br>
In another aspect the present invention provides a compound of the present invention which is<br>
selected from the group consisting of an human IL-4 specific monoclonal antibody (hll_-4 mAb), a<br>
fragment thereof and an analog thereof.<br>
An hlL-4 mAb is an antibody which specifically recognizes human IL-4, i.e. includes antigen<br>
binding sites specific for human IL-4, and which has specifically its CDRs but also other parts of<br>
the heavy and light chain derived from human immunoglobulins.<br>
The antibody may be of any isotype including lgG1, lgG2, IgGS and lgG4, preferably of isotype<br>
lgG1.<br>
"A fragment thereof means a part of the heavy and light chain variable sequence of a hlL-4 mAb,<br>
which retains the same antigen binding specificity and/or neutralizing ability as the molecule from<br>
which the fragments are derived, e.g. a Fab fragment or a F(ab')2 fragment derived from hlL-<br>
mAb.<br>
A Fab fragment contains the entire light chain and amino terminal portions of the heavy chain; a<br>
F(ab")2 fragment is the fragment formed by 2 Fab fragments bound by disulfide bonds. Such<br>
fragments can be obtained by conventional means, e.g. cleavage of the monoclonal antibodies<br>
with the appropriate proteolytic enzymes, papain and/or pepsin, or by recombinant methods, and<br>
the fragments themselves are useful as therapeutic and/or prophylactic agents.<br>
"An analog thereof means a hlL-4 mAb with an amino acid sequence which is modified by at least<br>
one amino acid outside of the CDR regions, e.g. outside of CDR1, CDR2 and CDRS of the heavy<br>
chain or outside of CDR1', CDR2' and CDR3' of the light chain. Said modification includes a<br>
chemical modification, a substitution or a rearrangement of one or a few amino acids, i.e. no more<br>
than 10 amino acids, which modification permits the amino acid sequence to retain the biological<br>
characteristics, e.g. antigen specificity and affinity, of the unmodified sequence. For example silent<br>
mutations can be constructed via substitution to create endonuclease restriction sites within or<br>
surrounding the CDR regions.<br>
6<br>
An analog may also arise as allelic variation. An "allelic variation or modification" is an alteration in<br>
the nucleic acid sequence encoding an antibody of the present invention outside of the CDR<br>
regions. Such alterations or modifications may be due to the degeneracies of the genetic code or<br>
may be liberately engineered to provide desired characteristics. Such variations or modifications<br>
may or may not result in alterations in any encoded amino acid sequence, but retain the biological<br>
activities, e.g. antigen specificity and affinity.<br>
We have also found polynucleotides encoding compounds of the present invention.<br>
In another aspect the present invention provides isolated polynucleotides comprising<br>
polynucleotides encoding a compound of the present invention.<br>
In another aspect the present invention provides polynucleotides encoding the amino acid<br>
sequence of CDR1, CDR2 and CDR3 of a compound of the present invention and polynucleotides<br>
encoding the amino acid sequence of CDR1', CDR2' and CDR3' of a compound of the present<br>
invention.<br>
In another aspect the present invention provides polynucleotides comprising<br>
a) a polynucleotide of SEQ ID NO:5 and a polynucleotide of SEQ ID NO:6, or<br>
b) a polynucleotide of SEQ ID NO:13 and a polynucleotide of SEQ ID NO:14, or<br>
c) a polynucleotide of SEQ ID NO:21 and a polynucleotide of SEQ ID NO:22, or<br>
d) a polynucleotide of SEQ ID NO:29 and a polynucleotide of SEQ ID NO:30, or<br>
e) a polynucleotide of SEQ ID NO:37 and a polynucleotide of SEQ ID NO:38, or<br>
f) a polynucleotide of SEQ ID NO:45 and a polynucleotide of SEQ ID NO:46.<br>
In another aspect the present invention provides polynucleotides encoding<br>
a) a polypeptide of SEQ ID NO:7 and SEQ ID NO:8, or<br>
b) a polypeptide of SEQ ID NO:15 and SEQ ID NO:16, or<br>
c) a polypeptide of SEQ ID NO:23 and SEQ ID NO:24, or<br>
d) a polypeptide of SEQ ID NO:31 and SEQ ID NO:32, or<br>
e) a polypeptide of SEQ ID NO:39 and SEQ ID NO:40, or<br>
0 a polypeptide of SEQ ID NO:47 and SEQ ID NO:48.<br>
SEQ ID NO:5 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:1.<br>
SEQ ID NO:6 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:2.<br>
SEQ ID NO:7 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:3.<br>
SEQ ID NO:8 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:4.<br>
SEQ ID NO:13 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:9.<br>
SEQ ID NO: 14 is a polynucleotide encoding an amino acid sequence of SEQ ID NO: 10.<br>
SEQ ID NO: 15 is a polynucleotide encoding an amino acid sequence of SEQ IDNO:11.<br>
SEQ ID NO: 16 is a polynucleotide encoding an amino acid sequence of SEQ ID NO: 12.<br>
SEQ ID NO:21 is a polynucleotide encoding an amino acid sequence of SEQ ID NO: 17.<br>
SEQ ID NO:22 is a polynucleotide encoding an amino acid sequence of SEQ ID NO: 18.<br>
SEQ ID NO:23 is a polynucleotide encoding an amino acid sequence of SEQ ID NO: 19.<br>
SEQ ID NO:24 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:20.<br>
SEQ ID NO:29 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:25.<br>
SEQ ID NO:30 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:26.<br>
SEQ ID NO:31 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:27.<br>
SEQ ID NO:32 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:28.<br>
SEQ ID NO:37 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:33.<br>
SEQ ID NO:38 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:34.<br>
SEQ ID NO:39 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:35.<br>
SEQ ID NO:40 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:36.<br>
SEQ ID NO:45 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:41.<br>
SEQ ID NO:46 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:42.<br>
SEQ ID NO:47 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:43.<br>
SEQ ID NO:48 is a polynucleotide encoding an amino acid sequence of SEQ ID NO:44.<br>
A compound of the present invention may be produced by recombinant DNA techniques. Thus,<br>
one or more DNA molecules encoding the antibody, a fragment thereof or an analog thereof may<br>
be constructed, placed under appropriate control sequences in an appropriate vector and<br>
transferred into a suitable host (organism) for expression. The compound of the present invention<br>
may be obtained according, e.g. analogously, to a method as conventional together with the<br>
information provided herein, e.g. with the knowledge of the amino acid sequence of the<br>
hypervariable and/or variable regions and the polynucleotides encoding these regions. A method<br>
for constructing a variable domain gene is e.g. described in EP 239 400 and may be briefly<br>
summarized as follows:<br>
A replicable expression vector including a suitable promoter operably linked to a polynucleotide<br>
sequence of interest, e.g. encoding at least a variable domain of an immunoglobulin heavy or light<br>
chain comprising CDRs, is prepared, a suitable cell line is transformed with said expression vector,<br>
the transformed cell line is cultured and the corresponding immunoglobulin is obtained.<br>
In another aspect the present invention provides an expression vector comprising a polynucleotide<br>
encoding a compound of the present invention, e.g. at least one polynucleotide of SEQ ID NO:5,<br>
SEQ ID NO: 6, SEQ ID NO:7, SEQ ID No:8, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, SEQ<br>
ID No:16, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID No:24, SEQ ID NO:37, SEQ ID<br>
NO:38, SEQ ID NO:39, SEQ ID No:40, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47 or SEQ ID<br>
No:48.<br>
Naturally an expression vector can comprise more than one polynucleotide.<br>
In another aspect the present invention provides<br>
- An expression system comprising a polynucleotide encoding a compound of the present<br>
invention wherein said expression system or part thereof is capable of producing a compound of<br>
the present invention, e.g. a hll_-4 mAb, when said expression system or part thereof is present<br>
in a compatible host cell; and<br>
- An isolated host cell comprising an expression system as defined above.<br>
Expression vectors, e.g. comprising suitable promoter(s) and genes encoding heavy and light<br>
chain constant parts are known, e.g. and are commercially available and include e.g. heavy chain<br>
vector lgG1 and light chain vector human kappa. A conventional expression vector or recombinant<br>
plasmid may be produced by placing the respective polynucleotide in operative association with<br>
conventional regulatory control sequences capable of controlling the replication and expression in,<br>
and/or secretion from, a host cell. Regulatory sequences include promoter sequences, e.g. CMV<br>
promoter, LCK promoter, and appropriate signal sequences.<br>
A selected host cell may be transfected by conventional techniques with the vector of interest to<br>
create a transfected host cell, which then may be cultured by conventional techniques to produce<br>
the compounds of the present invention.<br>
Appropriate cell lines may be found according, e.g. analogously, to a method as conventional.<br>
Appropriate hosts are known or may be found according, e.g. analogously, to a method as<br>
conventional and include cell cultures or transgenic animals.<br>
Suitable host cells or cell lines for the expression of the compounds of the present invention are<br>
preferably eukaryotic cells such as e.g. CHO, COS, a fibroblast cell (e.g. 3T3) and myeloid cells<br>
among others, preferably a mammalian cell, such as a CHO cell or SP2/0.<br>
The compounds of the present invention exhibit pharmacological activity and are therefore useful<br>
as Pharmaceuticals. E.g., the compounds of the present invention interfere strongly with the<br>
binding of IL-4 to an IL-4 receptor and are herein also referred to as IL-4 blocking or neutralizing<br>
compounds of the present invention, including hlL-4 mAb(s). Compounds of the present invention<br>
show activity and their affinity can be determined in the TEST:AFFINITY MEASUREMENT as<br>
described in Example 1.<br>
A compound of the present invention thus shows therapeutic activity against IL-4 and/or IgE<br>
mediated diseases, such as<br>
- various allergic diseases, e.g. including urticaria, allergic reactions to medication, rhinitis, e.g.<br>
allergic rhinitis, conjunctivitis, e.g. rhinoconjunctivitis, dermatitis, e.g. atopic dermatitis, asthma,<br>
e.g. atopic asthma and allergic asthma, anaphylactic shock;<br>
preferably atopic dermatitis, allergic asthma, allergic rhinitis, allergic rhinoconjunctivitis, such as<br>
allergic asthma or atopic dermatitis;<br>
- autoimmune diseases, including e.g. Kawasaki disease, Grave's disease, Sjorgen's syndrome,<br>
autoimmune lymphoproliferative syndrome, autoimmune haemolytic anemia, autoimmune uveitis,<br>
myasthenia gravis, Lupus Erythematosis and Bullous pemphigoid;<br>
- disorders of the digestive system in which IL-4 and/or IgE play a role, including e.g. ulcers, gastric<br>
inflammation, mucosal inflammation, ulcerative colitis, Crohn's disease, inflammatory bowel<br>
disease and other disorders of the digestive system in which IL-4 and/or IgE play a role;<br>
- diseases wherein IL-4 and/or IgE are overproduced and considered to contribute to pathology,<br>
including e.g. systemic sclerosis (scleroderma), septic arthritis and reactive arthritis.<br>
In another aspect the present invention provides a compound of the present invention, e.g. a hlL-4<br>
mAb, for use as a pharmaceutical, e.g. against IL-4 and/or IgE mediated diseases, e.g. allergic<br>
diseases, e.g. atopic dermatitis, allergic asthma, allergic rhinitis, preferably atopic dermatitis.<br>
In another aspect the present invention provides the use of the present invention of a compound of<br>
the present invention which is selected from the group consisting of a hlL-4 mAb, a fragment<br>
thereof and an analog thereof.<br>
For pharmaceutical use a compound of the present invention includes one or more, preferably one,<br>
compounds of the present invention, e.g. a combination of two or more compounds of the present<br>
invention.<br>
In another aspect the present invention provides the use of a compound of the present invention<br>
for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of<br>
diseases mediated by IL-4 and/or IgE, e.g. allergic diseases, e.g. allergic rhinoconjunctivitis, atopic<br>
dermatitis, allergic asthma, allergic rhinitis, preferably allergic asthma or atopic dermatitis, such as<br>
atopic dermatitis.<br>
10<br>
In a further aspect the present invention provides the use of a compound of the present invention<br>
for the manufacture of a medicament, e.g. a pharmaceutical composition, for the treatment of a<br>
disease as described above, e.g. selected from the group consisting of atopic dermatitis, allergic<br>
asthma and allergic rhinitis.<br>
In a further aspect the present invention provides a compound of the present invention for the uses<br>
as mentioned above, wherein the compound of the present invention is selected from the group<br>
consisting of a hlL-4 mAb, a fragment thereof and an analog thereof.<br>
It has, for example been determined that the affinity constant of a compound of the present<br>
invention, e.g. a hlL-4 mAb, a fragment thereof or an analog thereof, for human IL-4 is equal or<br>
less than 800 pM, e.g. is equal or less than 200 pM, such as of about 30 pM to about 200 pM,<br>
preferably of about 45 pM to about 170 pM, such as about 100 pM, more preferred about 50 pM,<br>
such as about 45 pM.<br>
It has, for example also been determined that the affinity constant of a compound of the present<br>
invention, e.g. a hlL-4 mAb, a fragment thereof or an analog thereof, for human IL-4 is of 30 pM to<br>
200 pM, preferably of 45 pM to 170 pM, such as 100 pM, more preferred 50 pM, such as 45 pM.<br>
It is therefore, indicated that for the treatment of diseases mediated by IL-4, the compounds of the<br>
present invention may be administered to larger mammals, for example humans, by similar modes<br>
of administration at similar dosages than conventionally used with monoclonal antibodies.<br>
In another aspect the present invention provides an antibody which binds to human IL-4 with a<br>
dissociation constant of equal or less than 200 pM, e.g. 30 to 200 pM.<br>
In a further aspect of the present invention the antibody for the uses as mentioned above is a hlL-4<br>
mAb, a fragment thereof or an analog thereof which binds to human IL-4 with a<br>
dissociation constant K<j of equal or less than pm e.g. to pm.></j>
In a further aspect the present invention provides a method of treatment of diseases which are<br>
mediated by IL-4 and/or IgE, e.g. allergic diseases, e.g. atopic dermatitis, allergic asthma, allergic<br>
rhinitis, preferably atopic dermatitis, which treatment comprises administering to a subject in need<br>
of such treatment an effective amount of a compound of the present invention; e.g. in the form of a<br>
pharmaceutical composition.<br>
In a further aspect of the present invention a compound of the present invention is administered in<br>
combination with another pharmaceutically active agent either simultaneously or in sequence.<br>
Treatment includes treatment and prophylaxis.<br>
For such treatment, the appropriate dosage will, of course, vary depending upon, for example, the<br>
chemical nature and the pharmacokinetic data of an antibody of the present invention employed,<br>
the individual host, the mode of administration and the nature and severity of the conditions being<br>
treated. However, in general, for satisfactory results in larger mammals, for example humans, an<br>
indicated daily dosage is in the range from, e.g. about, 0.1 ng/kg to, e.g. about, 10 mg/kg, such as<br>
from, e.g. about, 100 ng/kg to, e.g. about, 2 mg/kg of a compound of the present invention;<br>
conveniently administered, for example, in divided doses up to four times a day.<br>
A compound of the present invention may be administered by any conventional route, for example<br>
parenterally, e.g. including intravenous, intradermal, intramuscular, subcutaneous, intranasal<br>
administration, injectable solutions or suspensions or inhaler powder.<br>
In another aspect the present invention provides a pharmaceutical composition comprising a<br>
compound of the present invention in association with at least one pharmaceutical excipient, e.g.<br>
appropriate carrier and/or diluent, e.g. including fillers, binders, disintegrators, flow conditioners,<br>
lubricants, sugars and sweeteners, fragrances, preservatives, stabilizers, wetting agents and/or<br>
emulsifiers, solubilizers, salts for regulating osmotic pressure and/or buffers.<br>
In another aspect the present invention provides a pharmaceutical composition according to the<br>
present invention further comprising another pharmaceutically active agent.<br>
Such compositions may be manufactured according, e.g. analogously to a method as<br>
conventional, e.g. by mixing, granulating, coating, dissolving or lyophilizing processes. Unit dosage<br>
forms may contain, for example, from, e.g. about, 0.5 mg to, e.g. about, 1000 mg, such as 1 mg to<br>
about 500 mg.<br>
A compound of the present invention may be used for pharmaceutical treatment according to the<br>
present invention alone or in combination with one or more other pharmaceutically active agents.<br>
Such other pharmaceutically active agents include e.g. other antibodies, e.g. such as antibodies<br>
neutralizing IgE, cytokines or cytokine receptors, which are chosen according to the particular<br>
condition to be treated.<br>
Combinations include fixed combinations, in which two or more pharmaceutically active agents are<br>
in the same formulation; kits, in which two or more pharmaceutically active agents in separate<br>
formulations are sold in the same package, e.g. with instruction for co-administration; and free<br>
combinations in which the pharmaceutically active agents are packaged separately, but instruction<br>
for simultaneous or sequential administration are given.<br>
In another aspect the present invention also provides a method for diagnosing allergies and other<br>
conditions associated with excess IgE production in a human which comprises<br>
a) contacting a sample of a biological fluid with an antibody of the present invention, and<br>
b) assaying for the occurrence of binding between said antibody and human IL-4.<br>
In the following Examples all temperatures are in degrees Celsius (*C) and are unconnected.<br>
The following abbreviations are used:<br>
FACS buffer PBS, 2% PCS and 0.2% NaN3<br>
PCS fetal calf serum<br>
FITC fluoroescein isothiocyanat<br>
IC50 inhibitory concentration<br>
KLH keyhole limpet hemocyanin<br>
mAb monoclonal antibody<br>
MIX methotrexate<br>
PBS phosphate buffered saline<br>
slgD surface Immunoglobulin D<br>
rmlL-3 recombinant murine interleukin-3<br>
rhll_-4 recombinant human interleukin-4<br>
rhlL-13 recombinant human interleukin-13<br>
rpm revolutions per minute<br>
RPMI Roswell Park Memorial Institute medium<br>
RT room temperature<br>
TF-buffer 272 mM sucrose, 1 mM MgCI2, 7 mM phosphate buffer pH 7.4<br>
EXAMPLES<br>
EXAMPLE 1:<br>
a) Antibody production<br>
Plasmids encoding the variable regions of the sequence SEQ ID NO: 5 or 7 (= heavy chain) and<br>
the sequence SEQ ID NO: 6 or 8 (= light chain) of the antibody are cloned into expression<br>
cassettes for human kappa light chains and human lgG1 heavy chains.<br>
The specificity determining regions are combined with the necessary elements to generate<br>
complete monoclonal antibodies, i.e. promoter, leader sequence and splice donor sites for splicing<br>
to the antibody constant region exons that are required for the expression of functional<br>
immunoglobulin proteins. The variable region cassettes for the heavy and light chain antibodies,<br>
encoding for leader sequences, variable region and 3'- prime splice donor sites for splicing the<br>
constant region exons CH1-CH4 and kappa, are transferred into mammalian expression vetors HC<br>
(heavy chain vector, human lgG1) and LC (light chain vector, human kappa).<br>
The light chain containing plasmid.and the heavy chain containing plasmid are introduced into<br>
Sp2/0 cells in a co-transfection approach. E.g. for transfection, cells in exponential growth phase<br>
with a viability of about 95% are used. Cells are washed twice with cold TF-buffer and cell<br>
concentration is adjusted to 2 x 107 cells/ml in TF-buffer. 0.8 ml cell suspension obtained are mixed<br>
with 15 ng each of the heavy chain and light chain plasmid and placed on ice for 10 minutes.<br>
Transfection is done by electroporation using the Biorad Gene Pulser (280 V and 25 uF). After<br>
electroporation, cells are placed on ice for 15 minutes, transferred into 50 ml cold culture medium<br>
and incubated for 1 day at 37" and 5% CO2. For clonal amplification, the G418 resistant cells<br>
obtained are cultivated in the presence of 200 nM MTX. An aliquot of the heterogeneous cell pool<br>
is seeded into 96-well plates at clonal density of 1 viable cell/well in culture medium containing 200<br>
nM MTX allowing selection of clonal populations of amplified cells. Limiting dilution cloning is<br>
applied to generate clonal cell lines after amplification and adaptation to serum-free culture<br>
conditions. Cells are seeded into two 96-well plates at a concentration of 0.5 cell/well. Wells are<br>
screened microscopically for clonality one day after seeding. Only monoclonal antibodies are used<br>
for further testing.<br>
The antibody obtained comprises an amino acid sequence of SEQ ID NO:1 and SEQ ID NO:2.<br>
b) Affinity measurements<br>
Affinity measurements of human mAbs of the present invention are carried on a BIAcore™2000<br>
instrument. Anti-human IgG is coated onto a BIAcore sensorchip CM-5 (BIAcore), so that<br>
application of defined amounts of human mAbs results in capturing on this prepared surface and<br>
hence in a change of refractory properties that are measured. A subsequent application of rhlL-4<br>
results in a further change of the refractory properties, which allows determination of the<br>
association rate (Kon, on rate) as well as the dissociation rate (K^, off rate) and the product of<br>
these two, the affinity (K<j dissociation constant given in pm according to the biaevaluation></j>
software. Using several concentrations of rhlL-4 in BIAbuffer, an affinity of 43 pM of an mAb as<br>
defined by CDRs as described in claim 2a) is determined.<br>
c) Determination of inhibitory potential on IL-4 mediated IgE<br>
c1) Cell sources<br>
Human B cells are isolated from peripheral blood, respectively, buffy coats by Ficoll-paque density<br>
centrifugation, followed by magnetic separation with MACS beads (Miltenyi Biotech) specific for<br>
human CD 19 or human CD22 on an AutoMACS device.<br>
NaTve human B cells are similarly isolated using anti-human slgD FITC labeled goat F(ab')2<br>
antibodies followed by anti-FITC MACS beads.<br>
c2) Cell culture/maintenance<br>
Transfectants (BaF/3 transfectants carrying the IL-4Ra and the IL-13Ra1) are cultured in RPMI<br>
1640 medium supplemented with Glutamax (Invitrogen), 10% FCS, 1% penicillin/streptomycin and<br>
10 ng/ml rhlL-4 (Novartis). Cells are split 1:1 twice weekly, washed with fresh medium without<br>
rhlL-4 and kept in such medium overnight (=starved cells).<br>
Human ex vivo (naive) B cell cultures are incubated in X-Vivo medium (Cambrex, XV15)<br>
supplemented with Glutamax, 10% FCS, 1% penicillin/streptomycin in 96-well plates (Costar).<br>
c3) BAF cell proliferation assay<br>
Starved cells as described in b) are collected, washed with fresh medium, counted and adjusted to<br>
2 x 105 cells/ml of which 100 ul per well are distributed to 96-well plates (Costar). Fortitration<br>
series the cytokines rhlL-4, rhlL-13 and rmlL-3 are prepared in 4 times the desired final<br>
concentration in the same medium.<br>
For titration series antibodies are either used as cell culture supernatants with ELISA determined<br>
concentrations or from purified material at 4 times the desired concentrations in the same medium.<br>
The pre-dilutions of cytokines and antibodies are mixed at equal volumes and 100 pi of the pre-mix<br>
are transferred to the well prepared with cells. Controls are set up for background proliferation<br>
(medium without cytokine and without antibody = 100% inhibition) and maximum proliferation<br>
(medium with cytokine only = 0% inhibition).<br>
After overnight incubation at 37° in the presence of 5% CO2, [methyl-3H]thimidine (Amersham<br>
TRK120) 1 pCi per well is added in 10 ul of medium and incubated for 8 hours. Following a<br>
freeze/thaw cycle cells are harvested from the plates on filter mats using a Tomtek harvester. Filter<br>
mats are dried in a microwave oven for 2 minutes at 650 W and transferred to a sample bag<br>
together with a sheet of Meltilex Scintillation Wax (Wallac). Wax is melted through the filter and<br>
filters obtained are placed inside appropriate cassettes and inserted into a micro-beta reader<br>
(Wallac) for scintillation counting using a program measuring 30 seconds per field and<br>
extrapolating to counts per minutes.<br>
An ICso of 30 pM is measured in this test system for the antibody.<br>
c4) IL-4 induced CD23 up-regulation on B cells<br>
MACS separated B cells are adjusted to 0.5-1 x 106 cells/ml in XV15 and plated out in 100ul per<br>
well of 96 well round bottom plates. Cytokines (1 ng/ml final) and mAb (2 ug/ml - 2 ng/ml final) are<br>
pre-diluted and pre-mixed as described above and added in 100 ul to reach a final volume of<br>
200 pi.<br>
After culturing overnight at 37° in the presence of 5% CO2 cells are transferred to 96-well plates<br>
(Costar) and centrifuged at 2200 rpm (-1000 x g) for 1 minute after flicking off the supernatant<br>
washed with FACS buffer.<br>
Florochrome labeled mAbs [HLA-DR FITC (Caltag#MHLDR01 1:800), CD19 PE<br>
(Caltag#MHCD1904 1:200) and CD23 ARC (Caltag#MHCD2305 1:200)] are prepared in FACS<br>
buffer and distributed in 50ul per well. After 30-60 minutes incubation at RT, wells are filled up with<br>
FACS buffer, centrifuged and the centrifugation residue obtained is washed with FACS buffer.<br>
Cells are re-suspended in FACS buffer with 2ug/ml propidium iodide and analyzed on a dual laser<br>
FacsCalibur flow cytometer (BD Biosciences). Cells are gated according to their forward scatter<br>
and side scatter properties as well.as their ability to exclude propidium iodide and their CD19<br>
expression. Mean fluorescence intensities and percentage of cells above arbitrary threshold (set<br>
on un-induced cells) in CD23 expression are determined. Baseline expression (100% inhibition) is<br>
determined on cells without cytokine, whereas 0% inhibition is set on cells incubated with cytokine<br>
but without mAb.<br>
An IC50 of 334 pM for this antibody is determined for IL-4 induced CD23 expression on the cells as<br>
described above in the presence of 70 pM recombinant human IL-4.<br>
c5) IL-4 induced IgE production by naYve B cells<br>
Magnetically sorted naYve B cells are adjusted to 3 x 105 cells per ml in XV15 and plated out in<br>
100ul per well of 96-well plates in a 6 x 6 array in the center of the plate, surrounded by PBS filled<br>
wells during the 10 days of culture at 37° in the presence of 5% CO2. One plate each is prepared<br>
per mAb to be tested, consisting of 3 wells each un-induced and induced controls and quintuplicate<br>
repeats of mAb titrations starting at 7ug/ml and running in 3-fold dilution down to 29ng/ml final<br>
concentrations added in 50ul four times concentrated pre-dilution. Inducing conditions are rhlL-4 at<br>
20 ng/ml plus anti-CD40 mAb (Novartis) at 0.5ug/ml final concentrations also added in 50ul of four<br>
times concentrated pre-dilution. IgE concentrations are determined at the end of the culture period<br>
by a standard sandwich ELISA method.<br>
An IC50 of 2806 pM for this antibody is determined for IL-4 induced IgE on the cells as described<br>
above.<br>
Examples 2 to 6:<br>
Antibodies are obtained analogously as described in example 1 and comprise the following amino<br>
acid sequences:<br>
Example 2 is an antibody comprising amino acid sequence SEQ ID NO:9 and SEQ ID NO: 16<br>
Example 3 is an antibody comprising amino acid sequence SEQ ID NO: 17 and SEQ ID NO: 18.<br>
Example 4 is an antibody comprising amino acid sequence SEQ ID NO:25 and SEQ ID NO:26.<br>
Example 5 is an antibody comprising amino acid sequence SEQ ID NO:33 and SEQ ID NO:34.<br>
Example 6 is an antibody comprising amino acid sequence SEQ ID NO:41 and SEQ ID NO:42.<br>
(Table Removed)  summarizes the IC50 values of the antibodies in the various test systems as described in<br>
 (amino acid sequence of the mature polypeptide of the heavy chain, underlined amino acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVESGGGWQPGRSLRLSCAASGFTFSSYAMHWVRQAPGKGLEWVTFIWDDGSFKYYAES<br>
VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSWSPDIFDIWGQGTMVTVSS<br>
SEQ ID NO:2<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSYPITFGQGTRLEIKRT<br>
SEQ ID N0:3<br>
(amino acid sequence of the polypeptide of SEQ ID NO:1 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MEFGLNWVFLVALFRGVHCQVQLVESGGGWQPGRSLRLSCAASGFTFSSYAMHWVRQAPGK<br>
GLEWVTFIWDDGSFKYYAESVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSWSPDIFDI<br>
WGQGTMVTVSS<br>
SEQ ID NO:4<br>
17<br>
(amino acid sequence of the polypeptide of SEQ ID NO:2 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISRALAWYQQKPGK<br>
APKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPITFGQGTRLEIKRT<br>
SEQ ID NO:5<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:1)<br>
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT<br>
CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGCCATGCACTGGGTCCGCCAGGCTCCA<br>
GGCAAGGGGCTGGAGTGGGTGACATTTATATGGGATGATGGAAGTTTTAAATATTATGCAGAG<br>
TCCGTGAAGGGCCGATTCACCATCTCCAGAGACMTTCCAAGMCACGCTGTATTTGCAAATG<br>
AACAGCCTGAGAGCCGAAGACACGGCTGTGTATTACTGTGCGAGAGAGGGCAGCTGGTCTCC<br>
TGATATATTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQ ID NO:6<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:2)<br>
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC<br>
ACTTGCCGGGCAAGTCAGGGCATTAGCAGAGCTTTAGCCTGGTATCAGCAGAAACCAGGGAA<br>
AGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAG<br>
CGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGC<br>
AACTTATTACTGTCAACAGTTTAATAGTTACCCCATCACCTTCGGCCAAGGGACACGACTGGA<br>
GATTAAACGAACT<br>
SEQ ID NO:7<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:3)<br>
ATGGAGTTTGGGCTGAACTGGGTTTTCCTCGTTGCTCTTTTCAGAGGTGTCCACTGTCAGGTG<br>
CAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTG<br>
CAGCGTCTGGATTCACCTTCAGTAGCTATGCCATGCACTGGGTCCGCCAGGCTCCAGGCAAG<br>
GGGCTGGAGTGGGTGACATTTATATGGGATGATGGAAGTTTTAAATATTATGCAGAGTCCGTG<br>
AAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATTTGCAMTGAACAGC<br>
CTGAGAGCCGAAGACACGGCTGTGTATTACTGTGCGAGAGAGGGCAGCTGGTCTCCTGATAT<br>
ATTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQ ID NO:8<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:4)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCAG<br>
ATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCAC<br>
CATCACTTGCCGGGCAAGTCAGGGCATTAGCAGAGCTTTAGCCTGGTATCAGCAGAAACCAG<br>
GGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGT<br>
TCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGAT<br>
18<br>
TTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCCATCACCTTCGGCCAAGGGACACGAC<br>
TGGAGATTAAACGAACT<br>
SEQ ID NO:9<br>
(amino acid sequence of the mature polypeptide of the heavy chain, underlined amino acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVESGGGWQPGRSLRLSCAASGFTLSSFGMUWVRQAPGKGLEWVAVIWYDGSNEYYADS<br>
yKGRFTTSRDNSKNTLYLQMNSLRAEDTANA^YCAREGSWSPDIFDIWGQGTMVTVSS<br>
SEQ ID NO:10<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRTSQGIRSALAWYQQNPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSYPVTFGQGTRLEIKRT<br>
SEQ ID NO: 11<br>
(amino acid sequence of the polypeptide of SEQ ID NO:9 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MEFGLSWVFLVALLRGVQCQVQLVESGGGWQPGRSLRLSCAASGFTLSSFGMHWVRQAPGK<br>
GLEWVAVIWYDGSNEYYADSVKGRFTTSRDNSKNTLYLQMNSLRAEDTAWYCAREGSWSPDIF<br>
DIWGQGTMVTVSS<br>
SEQIDNO:12<br>
(amino acid sequence of the polypeptide of SEQ ID NO: 10 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRTSQGIRSALAWYQQNPGK<br>
APKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPVTFGQGTRLEIKRT<br>
SEQIDNO:13<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:9)<br>
CAGGTGCAACTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTC<br>
TCCTGTGCAGCGTCTGGATTCACCTTAAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCC<br>
AGGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATGAATACTATGCAG<br>
ACTCCGTGAAGGGCCGATTCACCACCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAA<br>
ATGAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGGCAGCTGGT<br>
CTCCTGATATTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQ ID NO:14<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO: 10)<br>
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC<br>
ACTTGCCGGACAAGTCAGGGCATTCGCAGTGCTTTAGCCTGGTATCAGCAGAACCCCGGGAA<br>
AGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAG<br>
CGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTG<br>
19<br>
CAACTTATTACTGTCAACAGTTTAATAGTTACCCCGTCACCTTCGGCCAAGGGACACGACTGG<br>
AGATTAAACGAACT<br>
SEQIDNO:15<br>
(nucleotides encoding an am/no acid sequence ofSEQ ID NO: 11)<br>
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTG<br>
CAACTGGTGGAGTCGGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTG<br>
CAGCGTCTGGATTCACCTTAAGTAGCTTTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAG<br>
GGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATGAATACTATGCAGACTCCGT<br>
GAAGGGCCGATTCACCACCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACA<br>
GCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGAGGGCAGCTGGTCTCCTGA<br>
TATTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQIDNO:16<br>
(nucleotides encoding an amino acid sequence ofSEQ ID NO: 12)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
CCATCACTTGCCGGACAAGTCAGGGCATTCGCAGTGCTTTAGCCTGGTATCAGCAGAACCCC<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCGCATCAAG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCCGTCACCTTCGGCCAAGGGACACG<br>
ACTGGAGATTAAACGAACT<br>
SEQ ID NO:17<br>
(amino acid sequence of the mature polypeptide of the heavy chain, underlined amino acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVESGGGMVQPGRSLRLSCAASGFTLSSYGMHWVRQAPGKGLEWVTVIWYDGNNQYYAD<br>
SyKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSWSPDIFDIWGQGTMVTVSS<br>
SEQIDNO:18<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSYPITFGQGTRLEIKRT<br>
SEQ ID NO:19<br>
(amino acid sequence of the polypeptide of SEQ ID NO: 17 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MEFGLSWVFLVALLRGVQCQVQLVESGGGMVQPGRSLRLSCAASGFTLSSYGMHWVRQAPGK<br>
GLEWVWIWYDGNNQYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAREGSWSPDIF<br>
DIWGQGTMVTVSS<br>
SEQ ID N0:20<br>
20<br>
(am/no acid sequence of the polypeptide ofSEQ ID NO: 18 with leader sequence, am/no acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISSYLAWYQQKPGK<br>
APKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPITFGQGTRLEIKRT<br>
SEQ ID N0:21<br>
(nucleotides encoding an am/no acid sequence of SEQ ID NO: 17)<br>
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCATGGTCCAGCCTGGGAGGTCCCTGAGACTCT<br>
CCTGTGCAGCGTCTGGATTCACCCTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCA<br>
GGCAAGGGGCTGGAGTGGGTGACAGTTATATGGTATGATGGAAATAATCAATACTATGCAGA<br>
CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT<br>
GAACAGCCTGAGAGCCGAGGACACGGCTGTATATTACTGTGCGAGAGAGGGCAGCTGGTCT<br>
CCTGATATTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQ ID NO:22<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO: 18)<br>
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC<br>
ACTTGCCGGGCAAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAGAAACCAGGGAA<br>
AGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAG<br>
CGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGMGATTTTG<br>
CAACTTATTACTGTCAACAGTTTMTAGTTACCCCATCACC1TCGGCCAAGGGACACGACTGG<br>
AGATTAAACGAACT<br>
SEQ ID NO:23<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO: 19)<br>
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTG<br>
CAGCTGGTGGAGTCTGGGGGAGGCATGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTG<br>
CAGCGTCTGGATTCACCCTCAGTAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAG<br>
GGGCTGGAGTGGGTGACAGTTATATGGTATGATGGAAATAATCAATACTATGCAGACTCCGTG<br>
AAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGC<br>
CTGAGAGCCGAGGACACGGCTGTATATTACTGTGCGAGAGAGGGCAGCTGGTCTCCTGATAT<br>
TTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA<br>
SEQ ID NO:24<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:20)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
CCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTTATTTAGCCTGGTATCAGCAGAAACCA<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCCATCACCTTCGGCCAAGGGACACG<br>
ACTGGAGATTAAACGAACT<br>
SEQ ID N0:25<br>
(amino acid sequence of the mature polypeptide of the heavy chain, underlined amino acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAISWVRQAPGQGFEWMGGIIPVIGTVNYEERF<br>
QDRVTITADNSTSTAYMELTSLRSEDTAVYFCGREEGFLDYWGQGTLVTVSS<br>
SEQ ID NO:26<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSYPLLTFGGGTKVEIKRT<br>
SEQ ID N0:27<br>
(amino acid sequence of the polypeptide of SEQ ID NO:25 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MD.WTWRFLFWAAATGVQSQVQLVQSGAEVKKPGSSVKVSCKASGDTFSSYAISWVRQAPGQ<br>
GFEWMGGIIPVIGTVNYEERFQDRVTITADNSTSTAYMELTSLRSEDTANA'FCGREEGFLDYWGQ<br>
GTLVTVSS<br>
SEQ ID NO:28<br>
(amino acid sequence of the polypeptide of SEQ ID NO:26 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKP<br>
GKAPKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPLLTFGGGTK<br>
VEIKRT<br>
SEQ ID N0:29<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:25)<br>
CAGGTCCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT<br>
CCTGCMGGCTTCTGGAGACACCTTCAGCAGTTATGCTATCAGTTGGGTGCGACAGGCCCCT<br>
GGACAAGGGTTTGAGTGGATGGGAGGGATCATCCCTGTCATTGGTACAGTAAATTATGAAGA<br>
GAGATTCCAGGACAGAGTCACGATTACCGCGGACAATTCCACGAGCACAGCCTACATGGAGT<br>
TGACTAGTCTGAGATCTGAAGACACGGCCGTGTAI I I I IGTGGGAGAGAAGAGGGCTTCCTT<br>
GACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCCTCA<br>
SEQ ID NO:30<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:26)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
CCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCA<br>
22<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCAACTTATTACTGTCAACAGTTTAATAGTTACCCTCTTCTCACTTTCGGCGGAGGGAC<br>
CAAGGTGGAGATCAAACGTACG<br>
SEQ ID NO:31<br>
(nucleotides encoding an am/no acid sequence of SEQ ID NO:27)<br>
ATGGACTGGACCTGGAGGTTCCTCTTTGTGGTGGCAGCAGCTACAGGTGTCCAGTCCCAGGT<br>
CCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGC<br>
AAGGCTTCTGGAGACACCTTCAGCAGTTATGCTATCAGTTGGGTGCGACAGGCCCCTGGACA<br>
AGGGTTTGAGTGGATGGGAGGGATCATCCCTGTCATTGGTACAGTAAATTATGAAGAGAGATT<br>
CCAGGACAGAGTCACGATTACCGCGGACAATTCCACGAGCACAGCCTACATGGAGTTGACTA<br>
GTCTGAGATCTGAAGACACGGCCGTGTATTTTTGTGGGAGAGAAGAGGGCTTCCTTGACTATT<br>
GGGGCCAGGGAACCCTGGTCACCGTCTCCTCA<br>
SEQ ID NO:32<br>
(nucleotides encoding an am/no acid sequence of SEQ ID NO:28)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
CCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCA<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCMG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCMCTTATTACTGTCMCAGTTTAATAGTTACCCTCTTCTCACTTTCGGCGGAGGGAC<br>
CAAGGTGGAGATCAAACGTACG<br>
SEQ ID NO:33<br>
(amino acid sequence of the mature polypeptide of the heavy chain, underlined am/no acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVESGGGWQPGRSLRLSCAASGFTFSCCGMHWVRQAPGKGLEWVAVIWYDGSNKYYAD<br>
S^KGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCATDSSGSFYEYFQHWGQGTLVTVSS<br>
SEQ ID NO:34<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRASQGINSAU\WYQQKPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSYPYTFGQGTKLEIKRT<br>
SEQ ID NO:35<br>
(amino acid sequence of the polypeptide of SEQ ID NO:33 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
23<br>
MEFGLSWVFLVALLRGVQCQVQLVESGGGWQPGRSLRLSCAASGFTFSCCGMHWVRQAPGK<br>
GLEWVAVIWYDGSNKYYADSVKGRFTISRDTSKNTLYLQMNSLRAEDTAVYYCATDSSGSFYEYF<br>
QHWGQGTLVTVSS<br>
SEQ ID NO:36<br>
(amino acid sequence of the polypeptide of SEQ ID NO:34 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGINSALAWYQQKPGK<br>
APKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPYTFGQGTKLEIKRT<br>
SEQ ID NO:37<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:33)<br>
CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT<br>
CCTGTGCAGCGTCTGGATTCACCTTCAGTTGCTGTGGCATGCACTGGGTCCGCCAGGCTCCA<br>
GGCAAGGGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGA<br>
CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACACTTCCAAGAACACGCTGTATCTGCAAAT<br>
GAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGACAGATAGTTCGGGGAGTT<br>
TTTATGAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA<br>
SEQ ID NO:38<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:34)<br>
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC<br>
ACTTGCCGGGCAAGTCAGGGCATTAACAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAA<br>
AGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAGGTTCAG<br>
CGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTG<br>
CAACTTATTACTGTCAACAGTTTAATAGTTACCCGTACACTTTTGGCCAGGGGACCAAGCTGG<br>
AGATCAAACGAACT<br>
SEQ ID NO:39<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:35)<br>
ATGGAGTTTGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTG<br>
CAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTG<br>
CAGCGTCTGGATTCACCTTCAGTTGCTGTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAG<br>
GGGCTGGAGTGGGTGGCAGTTATATGGTATGATGGAAGTAATAAATACTATGCAGACTCCGT<br>
GAAGGGCCGATTCACCATCTCCAGAGACACTTCCAAGAACACGCTGTATCTGCAAATGAACA<br>
GCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGACAGATAGTTCGGGGAGI II I I AT<br>
GAATACTTCCAGCACTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA<br>
SEQ ID NO:40<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:36)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
24<br>
CCATCACTTGCCGGGCAAGTCAGGGCATTAACAGTGCTTTAGCCTGGTATCAGCAGAAACCA<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCMCTTATTACTGTCAACAGTTTAATAGTTACCCGTACACTTTTGGCCAGGGGACCAA<br>
GCTGGAGATCAAACGAACT<br>
SEQ ID NO:41<br>
Cam/no acid sequence of the mature polypeptide of the heavy chain, underlined am/no acids<br>
correspond to CDR1, CDR2 and CDR3)<br>
QVQLVESGGGWQPGRSLRLSCAASGFTFSGYGMHWVRQAPGRGLDWVAWWYDGGYKFYA<br>
DSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSGSFYEYLQHWGQGTLVTVSS<br>
SEQ ID NO:42<br>
(amino acid sequence of the mature polypeptide of the light chain, underlined amino acids<br>
correspond to CDR1', CDR2' and CDR3')<br>
AIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSG<br>
SGTDFTLTISSLQPEDFATYYCQQFNSY£HFWPGDQAGDQTNCG<br>
SEQ ID NO:43<br>
(amino acid sequence of the polypeptide of SEQ ID NO:41 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MEFGLSWVFLVALLRGVQCQVQLVESGGGWQPGRSLRLSCAASGFTFSGYGMHWVRQAPGR<br>
GLDWVANAWYDGGYKFYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDSSGSFYEY<br>
LQHWGQGTLVTVSS<br>
SEQ ID NO:44<br>
(amino acid sequence of the polypeptide of SEQ ID NO:42 with leader sequence, amino acids<br>
marked in bold correspond to the leader sequence)<br>
MDMRVPAQLLGLLLLWLPGARCAIQLTQSPSSLSASVGDRVTITCRASQGISSALAWYQQKPGK<br>
APKLLIYDASSLESGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFNSYPHFWPGDQAGDQT<br>
NCG<br>
SEQ ID NO:45<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:41)<br>
CAGGTGCAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT<br>
CCTGTGCAGCGTCTGGATTCACCTTCAGTGGCTATGGCATGCACTGGGTCCGCCAGGCTCCA<br>
GGCAGGGGGCTGGACTGGGTGGCAGTTGTGTGGTATGATGGAGGTTATAAGTTCTATGCAGA<br>
CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT<br>
GAACAGCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATAGTTCGGGGAGTT<br>
TTTATGAATACTTACAACATTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA<br>
SEQ ID NO:46<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:42)<br>
25<br>
GCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATC<br>
ACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCAGGGAA<br>
AGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTrGGAAAGTGGGGTCCCATCAAGGTTCAG<br>
CGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTG<br>
CAACTTATTACTGTCAACAGTTTAATAGTTACCCTCACTTTTGGCCAGGGGACCAAGCTGGAG<br>
ATCAAACGAACT<br>
SEQ ID NO:47<br>
(nucleotides encoding an am/no acid sequence of SEQ IDNO:43)<br>
ATGGAGT7TGGGCTGAGCTGGGTTTTCCTCGTTGCTCTTTTAAGAGGTGTCCAGTGTCAGGTG<br>
CAGTTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTG<br>
CAGCGTCTGGATTCACCTTCAGTGGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAG<br>
GGGGCTGGACTGGGTGGCAGTTGTGTGGTATGATGGAGGTTATAAGTTCTATGCAGACTCCG<br>
TGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACA<br>
GCCTGAGAGCCGAGGACACGGCTGTGTATTACTGTGCGAGAGATAGTTCGGGGAGI I I I I AT<br>
GAATACTTACAACATTGGGGCCAGGGCACCCTGGTCACCGTCTCCTCA<br>
SEQ ID N0:48<br>
(nucleotides encoding an amino acid sequence of SEQ ID NO:44)<br>
ATGGACATGAGGGTCCCCGCTCAGCTCCTGGGGCTTCTGCTGCTCTGGCTCCCAGGTGCCA<br>
GATGTGCCATCCAGTTGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCA<br>
CCATCACTTGCCGGGCAAGTCAGGGCATTAGCAGTGCTTTAGCCTGGTATCAGCAGAAACCA<br>
GGGAAAGCTCCTAAGCTCCTGATCTATGATGCCTCCAGTTTGGAAAGTGGGGTCCCATCAAG<br>
GTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAG<br>
ATTTTGCAACTTATTACTGTCMCAGTTTAATAGTTACCCTCACTTTTGGCCAGGGGACCAAGC<br>
TGGAGATCAAACGAACT<br><br><br>
Patent Claims<br>
1. An human IL-4 specific antibody which binds to human IL-4 with a dissociation constant Kj of<br>
equal or less than 800 pM.<br>
2. An antibody of claim 1 having a first domain comprising in sequence the hypervariaWe regions<br>
CDR1, CDR2 and CDR3 and a second domain comprising in sequence the hypervariable<br>
regions CDR1', CDR21 and CDR31 selected from the group consisting of an antibody wherein<br>
a) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Ser-Tyr-Ala-Met-His,<br>
said CDR2 has the amino acid sequence Phe-lle-Trp-Asp-Asp-Gly-Ser-Phe-Lys-Tyr-Tyr-<br>
Ala-Glu-Ser-Val-Lys-Gly,<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe,<br>
said CDRV has the amino acid sequence Ser-Gln-Gly-lle-Ser-Arg-Ala,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-lle,<br>
b) said CDR1 has the amino acid sequence Gly-Phe-Thr-Leu-Ser-Ser-Phe-Gly-Met-His,<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Glu-Tyr-Tyr-Ala-<br>
Asp-Ser-Val-Lys-Gly,<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe,<br>
said CDRV has the amino acid sequence Ser-Gln-Gly-lle-Arg-Ser-Ala,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Val,<br>
c) said CDR1 has the amino acid sequence Gly-Phe-Thr-Leu-Ser-Ser-Tyr-Gly-Met-His,<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Asn-Asn-Gln-Tyr-Tyr-Ala-<br>
Asp-Ser-Val-Lys-Gly,<br>
said CDR3 has the amino acid sequence Glu-Gly-Ser-Trp-Ser-Pro-Asp-lle-Phe,<br>
said CDR11 has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Tyr,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR31 has the amino acid sequence Phe-Asn-Ser-Tyr-Pro,<br>
d) said CDR1 has the amino acid sequence Gly-Asp-Thr-Phe-Ser-Ser-Tyr-Ala-lle-Ser,<br>
said CDR2 has the amino acid sequence Gly-lle-lle-lle-Pro-Val-lle-Gly-Thr-Val-Asn-Tyr-<br>
Glu-Glu-Arg-Phe-Gln-Asp-Arg,<br>
said CDR3 has the amino acid sequence Glu-Glu-Gly-Phe-Leu,<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Ala,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Leu,<br>
e) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Cys-Cys-Gly-Met-His,<br>
27<br>
said CDR2 has the amino acid sequence Val-lle-Trp-Tyr-Asp-Gly-Ser-Asn-Lys-Tyr-Tyr-Ala-<br>
Asp-Ser-Val-Lys-Gly,<br>
said CDR3 has the amino acid sequence Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Phe,<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Asn-Ser-Ala,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-Tyr, and<br>
f) said CDR1 has the amino acid sequence Gly-Phe-Thr-Phe-Ser-Gly-Tyr-Gly-Met-His,<br>
said CDR2 has the amino acid sequence Val-Val-Trp-Tyr-Asp-Gly-Gly-Tyr-Lys-Phe-Tyr-<br>
Ala-Asp-Ser-Val-Lys-Gly,<br>
said CDR3 has the amino acid sequence Asp-Ser-Ser-Gly-Ser-Phe-Tyr-Glu-Tyr-Leu,<br>
said CDR1' has the amino acid sequence Ser-Gln-Gly-lle-Ser-Ser-Ala,<br>
said CDR2' has the amino acid sequence Asp-Ala-Ser,<br>
said CDR3' has the amino acid sequence Phe-Asn-Ser-Tyr-Pro-His.<br>
3. An antibody of claim 1 or 2 comprising<br>
a) a polypeptide of SEQ ID NO:1 and a polypeptide of SEQ ID NO:2, or<br>
b) a polypeptide of SEQ ID NO:9 and a polypeptide of SEQ ID NO: 10, or<br>
c) a polypeptide of SEQ ID NO:17 and a polypeptide of SEQ ID NO:18, or<br>
d) a polypeptide of SEQ ID NO:25 and a polypeptide of SEQ ID NO:26, or<br>
e) a polypeptide of SEQ ID NO:33 and a polypeptide of SEQ ID NO:34, or<br>
f) a polypeptide of SEQ ID NO:41 and a polypeptide of SEQ ID NO:42.<br>
4. An antibody of any one of claims 1 to 3 comprising<br>
a) a polypeptide of SEQ ID NO:3 and a polypeptide of SEQ ID NO:4, or<br>
b) a polypeptide of SEQ ID NO:11 and a polypeptide of SEQ ID NO:12, or<br>
c) a polypeptide of SEQ ID NO:19 and a polypeptide of SEQ ID NO:20, or<br>
d) a polypeptide of SEQ ID NO:27 and a polypeptide of SEQ ID NO:28, or<br>
e) a polypeptide of SEQ ID NO:35 and a polypeptide of SEQ ID NO:36, or<br>
f) a polypeptide of SEQ ID NO:43 and a polypeptide of SEQ ID NO:44.<br>
5. An antibody of any one of claims 1 to 4 which is selected from the group consisting of<br>
an human IL-4 specific monoclonal antibody, a fragment thereof and an analog thereof.<br>
6. Isolated polynucleotides comprising polynucleotides encoding an antibody of claim 1.<br>
7. Polynucleotides of claim 6 encoding the amino acid sequence of an antibody of any one of<br>
claims 2 to 5.<br>
8. Polynucleotides of any one of claims 6 or 7 comprising<br>
a) a polynucleotide of SEQ ID NO:5 and a polynucleotide of SEQ ID NO:6, or<br>
b) a polynucleotide of SEQ ID NO:13 and a polynucleotide of SEQ ID NO:14, or<br>
c) a polynucleotide of SEQ ID NO:21 and a polynucleotide of SEQ ID NO:22, or<br>
d) a polynucleotide of SEQ ID NO:29 and a polynucleotide of SEQ ID NO:30, or<br>
e) a polynucleotide of SEQ ID NO:37 and a polynucleotide of SEQ ID NO:38, or<br>
f) a polynucleotide of SEQ ID NO:45 and a polynucleotide of SEQ ID NO:46.<br>
9. Polynucleotides of any one of claims 6 to 8 encoding<br>
a) a polypeptide of SEQ ID NO:7 and SEQ ID NO:8, or<br>
b) a polypeptide of SEQ ID NO:15 and SEQ ID NO:16, or<br>
c) a polypeptide of SEQ ID NO:23 and SEQ ID NO:24, or<br>
d) a polypeptide of SEQ ID NO:31 and SEQ ID NO:32, or<br>
e) a polypeptide of SEQ ID NO:39 and SEQ ID NO:40, or<br>
f) a polypeptide of SEQ ID NO:47 and SEQ ID NO:48.<br>
10. An expression vector comprising polynucleotides of any one of claims 6 to 9.<br>
11. An expression system comprising a polynucleotide of any one of claims 6 to 9 wherein said<br>
expression system or part thereof is capable of producing an antibody of any one of claims 1<br>
to 5 when said expression system or part thereof is present in a compatible host cell.<br>
12. An isolated host cell comprising an expression system of claim 11.<br>
13. Use of an antibody of any one of claims 1 to 5 as a pharmaceutical.<br>
14. Use of an antibody of any one of claims 1 to 5 for the manufacture of a medicament for the<br>
treatment of diseases mediated by IL-4 and/or IgE.<br>
15. Use of claim 14 wherein the disease is selected from the group consisting of atopic dermatitis,<br>
allergic asthma and allergic rhinitis.<br>
16. Use of any one of claims 13 to 15 wherein the antibody is selected from the group<br>
consisting of an human IL-4 monoclonal antibody, a fragment thereof and an analog thereof.<br>
17. A pharmaceutical composition comprising an antibody of any one of claims 1 to 5 in<br>
29<br>
association with at least one pharmaceutically acceptable excipient.<br>
18. A method of treatment of diseases mediated by IL-4 and/or IgE which treatment comprises<br>
administering to a subject in need of such treatment an effective amount of an antibody of any one of claims1to5.<br></td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUFic3RyYWN0LSgyNi0wMi0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Abstract-(26-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWFic3RyYWN0LnBkZg==" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-abstract.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUFzc2lnbm1lbnQtKDI4LTAxLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Assignment-(28-01-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUNsYWltcy0oMjYtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Claims-(26-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWNsYWltcy5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-claims.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjYtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Correspondence Others-(26-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlIE90aGVycy0oMjgtMDEtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Correspondence Others-(28-01-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMDUtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Correspondence-Others-(05-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUNvcnJlc3BvbmRlbmNlLU90aGVycy0oMjctMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Correspondence-Others-(27-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWNvcnJlc3BvbmRlbmNlLW90aGVycy5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-correspondence-others.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWRlc2NyaXB0aW9uIChjb21wbGV0ZSkucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-description (complete).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWZvcm0tMS5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWZvcm0tMi5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-form-2.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUZvcm0tMy0oMDUtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Form-3-(05-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUZvcm0tMy0oMjYtMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Form-3-(26-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWZvcm0tMy5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LWZvcm0tNS5wZGY=" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LUdQQS0oMjgtMDEtMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-GPA-(28-01-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LXBjdC0yMTAucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-pct-210.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LXBjdC0yMzcucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-pct-237.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LXBjdC0zNzMucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-pct-373.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LXBjdC1ub3RpZmljYXRpb24ucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-pct-notification.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LVBldGl0aW9uLTEzNy0oMjctMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Petition-137-(27-02-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTEyMS1kZWxucC0yMDA3LVBldGl0aW9uLTEzOC0oMjctMDItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1121-delnp-2007-Petition-138-(27-02-2013).pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="256774-stabilised-oxygen-releasing-composition.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="256776-solid-phase-oligosaccharide-tagging-a-technique-for-manipulation-of-immobilized-carbohydrates.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>256775</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1121/DELNP/2007</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>31/2013</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>02-Aug-2013</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>29-Jul-2013</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>09-Feb-2007</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>NOVARTIS AG.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>LICHTSTRASSE 35, CH-4056 BASEL SWITZERLAND.</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>CARBALLIDO HERRERA JOSE M.</td>
											<td>BERNHARD WEISSGASSE 6/3, A-2380 PERCHTOLDSDORF AUSTRIA.</td>
										</tr>
										<tr>
											<td>2</td>
											<td>DE VRIES JAN E.</td>
											<td>NEUE WELT GASSE 16/1, A-1130 WIEN AUSTRIA.</td>
										</tr>
										<tr>
											<td>3</td>
											<td>SCHWAERZLER CHRISTOPH</td>
											<td>ARNDTSTRASSE 42/37R, A-1120 WIEN AUSTRIA.</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C07K 16/24</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/EP2005/008361</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2005-08-02</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td>0417301.9</td>
									<td>2004-08-03</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>2</td>
									<td>0417302.7</td>
									<td>2004-08-03</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>3</td>
									<td>0417304.3</td>
									<td>2004-08-03</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>4</td>
									<td>0417306.8</td>
									<td>2004-08-03</td>
								    <td>U.K.</td>
								</tr>
								<tr>
									<td>5</td>
									<td>0417303.5</td>
									<td>2004-08-03</td>
								    <td>U.K.</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/256775-human-monoclonal-antibodies-against-human-il-4 by HTTrack Website Copier/3.x [XR&CO'2014], Fri, 05 Apr 2024 09:10:59 GMT -->
</html>
